Stephen J Smith, MD
Ophthalmology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Offices
- 3
Offices
3 locations · Stanford Health Care · County of Santa Clara
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Smith’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A141803 · Current
Licensed to practise in California · since 2016 · expires 2028-04-30 · Mayo Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$675,167
Medicare paid this office $675,167 for 1,476 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 1,280 | $288,524 | $82 |
| Injection of drug into eye | 307 | $182,840 | $93 |
| Imaging of retina | 1,406 | $80,650 | $22 |
| New patient visit (45+ min) | 237 | $26,608 | $112 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 948 | $18,605 | $15 |
See all 14 services
| Return visit (30+ min) | 1,280 | $288,524 | $82 |
| Injection of drug into eye | 307 | $182,840 | $93 |
| Imaging of retina | 1,406 | $80,650 | $22 |
| New patient visit (45+ min) | 237 | $26,608 | $112 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 948 | $18,605 | $15 |
| Destruction of leaking blood vessels of retina using laser | 17 | $9,760 | $287 |
| Removal of recurring cataract in lens capsule using a laser | 28 | $9,742 | $263 |
| Long return visit (40+ min) | 39 | $6,555 | $129 |
| Photocoagulation treatment to prevent detachment of retina | 23 | $5,479 | $211 |
| Removal of eye fluid | 39 | $3,680 | $68 |
| Short return visit (20+ min) | 51 | $3,197 | $56 |
| 2d ultrasound scan of eye tissue and structures | 43 | $1,281 | $27 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 15 | $551 | $37 |
| Imaging of optic nerve | 16 | $318 | $20 |
Procedures Medicare counted
| Cataract surgery | 41 | More than 59% of doctors who do this |
Who their Medicare patients are
1,476 Original Medicare patients in 2024. Average age 75 · Under 65 7% · 85 and older 17% · Women 55% · Also on Medicaid 28% · Health risk score 1.42. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 71% · Diabetes 45% · Coronary heart disease 26% · Chronic kidney disease 25% · Atrial fibrillation 16% · Cancer 15% · Depression 15% · Heart failure 14% · Stroke 9% · COPD 8% · Dementia 5%.
The office billed $4,777,976, Medicare allowed $895,633 and paid $675,167; for 11,100 services of 36 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,476 | 11,100 | 75 | 1.42 | $4,777,976 | $675,167 |
| 2023 | 1,005 | 5,900 | 74 | 1.48 | $2,532,599 | $419,474 |
| 2022 | 644 | 2,820 | 74 | 1.27 | $1,035,522 | $213,597 |
| 2021 | 142 | 434 | 75 | 1.30 | $189,591 | $37,551 |
| 2018 | 55 | 63 | 75 | 1.36 | $84,073 | $5,123 |
| 2017 | 104 | 124 | 73 | 1.21 | $216,070 | $10,953 |
| 2016 | 93 | 101 | 74 | 1.28 | $193,721 | $9,166 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Return visit (30+ min) | 769 | $162,542 | $87 |
| Injection of drug into eye | 237 | $123,149 | $99 |
| Imaging of retina | 931 | $51,910 | $23 |
| New patient visit (45+ min) | 251 | $27,340 | $109 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 11 | $11,835 | $1,076 |
| Short return visit (20+ min) | 57 | $3,965 | $59 |
| Return visit (30+ min) | 12 | $1,058 | $88 |
| Short return visit | 24 | $817 | $33 |
| 2d ultrasound scan of eye tissue and structures | 22 | $737 | $29 |
| Imaging of retina | 26 | $621 | $22 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 15 | $614 | $41 |
| Photography of the retina | 14 | $302 | $20 |
2022: 9 services
| Return visit (30+ min) | 363 | $68,862 | $87 |
| Injection of drug into eye | 134 | $47,382 | $98 |
| New patient visit (45+ min) | 323 | $36,534 | $113 |
| Imaging of retina | 598 | $24,533 | $23 |
| Destruction of leaking blood vessels of retina using laser | 13 | $8,958 | $299 |
| Photocoagulation treatment to prevent detachment of retina | 13 | $3,392 | $212 |
| Short return visit (20+ min) | 19 | $1,239 | $56 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 25 | $929 | $37 |
| Photography of the retina | 12 | $237 | $18 |
2021: 4 services
| Return visit (30+ min) | 76 | $9,408 | $87 |
| New patient visit (45+ min) | 61 | $7,392 | $121 |
| Injection of drug into eye | 19 | $5,908 | $102 |
| Imaging of retina | 133 | $4,065 | $23 |
2018: 1 service
| Short return visit (20+ min) | 19 | $786 | $41 |
2017: 5 services
| Complex repair of detached retina and drainage of eye fluid between lens and retina | 11 | $2,431 | $203 |
| Removal of eye fluid (vitreous) between lens and retina | 14 | $2,194 | $137 |
| Return visit (30+ min) | 15 | $939 | $59 |
| Short return visit (20+ min) | 18 | $706 | $39 |
| Short return visit | 18 | $409 | $22 |
2016: 4 services
| Removal of membrane of retina with removal of internal limiting membrane of retina | 15 | $2,605 | $174 |
| Return visit (30+ min) | 14 | $981 | $70 |
| Short return visit (20+ min) | 15 | $664 | $44 |
| Photography of the retina | 12 | $267 | $22 |
Medicaid work
$817,825 in 2024
Medicaid paid $817,825 for 7,940 billed services this clinician did in 2024, up to 184 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Aflibercept injection | 231 | $401,210 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 2,392 | $283,873 |
| Return visit (30+ min) | 1,492 | $58,906 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 2,092 | $23,488 |
| Service | 562 | $22,048 |
| OFF/OP EST MAY X REQ PHY/QHP | 197 | $8,387 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 40 | $4,941 |
| Injection, bevacizumab, 10 mg | 15 | $4,425 |
| TREATMENT X10SV RETINOPATHY | 24 | $4,149 |
| Hospital outpatient clinic visit for assessment and management of a patient | 303 | $3,088 |
| Long return visit (40+ min) | 13 | $1,449 |
| New patient visit (45+ min) | 18 | $931 |
| 2024 | 7,940 | 16 | 184 | $817,825 |
| 2023 | 6,616 | 12 | 171 | $801,302 |
| 2022 | 2,359 | 10 | 113 | $183,351 |
| 2021 | 116 | 2 | 22 | $2,266 |
See the largest Medicaid services in earlier years
2023
| Aflibercept injection | 193 | $388,872 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 2,136 | $281,528 |
| Injection, bevacizumab, 10 mg | 136 | $44,245 |
| Return visit (30+ min) | 1,285 | $35,156 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 1,878 | $23,695 |
| Service | 357 | $14,234 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 83 | $9,420 |
| OFF/OP EST MAY X REQ PHY/QHP | 63 | $1,994 |
| Hospital outpatient clinic visit for assessment and management of a patient | 242 | $1,938 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 65 | $143 |
| New patient visit (45+ min) | 14 | $75 |
| Advance Care Planning discussed and documented advance care plan or surrogate decision maker documented in the medical record (DEM) (GER, Pall Cr) | 164 | $0 |
2022
| Intravitreal injection of a pharmacologic agent (separate procedure) | 701 | $104,738 |
| Aflibercept injection | 12 | $23,333 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 130 | $14,887 |
| Return visit (30+ min) | 482 | $14,336 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 770 | $12,775 |
| Injection, bevacizumab, 10 mg | 26 | $9,365 |
| Service | 102 | $2,926 |
| New patient visit (45+ min) | 61 | $897 |
| Hospital outpatient clinic visit for assessment and management of a patient | 31 | $95 |
| Advance Care Planning discussed and documented advance care plan or surrogate decision maker documented in the medical record (DEM) (GER, Pall Cr) | 44 | $0 |
2021
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 87 | $1,453 |
| Return visit (30+ min) | 29 | $813 |
Drugs they prescribed that Part D paid
$11,931
Pharmacies billed $11,931 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 156) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
75 generic and 81 brand-name prescriptions · $11,931 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prednisolone Acetate | 53 | $2,946 | $56 |
| Ketorolac Tromethamine | 25 | $741 | $30 |
| Dorzolamide-Timolol | 26 | $176 | $7 |
Year by year
| 2024 | 156 | 66 | 0% (0) | 52% | $11,931 |
| 2023 | 162 | 63 | 0% (0) | 58% | $16,908 |
| 2022 | 60 | 25 | 0% (0) | 37% | $8,658 |
| 2019 | 17 | None | 0% (0) | 0% | $318 |
| 2018 | 84 | 28 | 0% (0) | 46% | $54,642 |
| 2017 | 79 | 47 | 0% (0) | 68% | $116,120 |
| 2016 | 305 | 112 | None | 36% | $22,532 |
| 2015 | 155 | 76 | None | None | $11,800 |
| 2014 | 157 | 74 | 17% (26) | 32% | $13,894 |
| 2013 | 79 | 47 | None | 48% | $4,995 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Prednisolone Acetate | 67 | $4,148 | $62 |
| Ketorolac Tromethamine | 25 | $1,266 | $51 |
| Dorzolamide-Timolol | 15 | $269 | $18 |
| Latanoprost | 14 | $88 | $6 |
2022: 2 drugs
| Prednisolone Acetate | 11 | $791 | $72 |
| Azelastine | 12 | $193 | $16 |
2019: 1 drug
| Donepezil | 11 | $206 | $19 |
2018: 2 drugs
| Donepezil | 11 | $194 | $18 |
| Latanoprost | 16 | $166 | $10 |
2017: 1 drug
| Prednisolone Acetate | 19 | $1,268 | $67 |
2016: 8 drugs
| Restasis | 13 | $7,219 | $555 |
| Prednisolone Acetate | 37 | $2,869 | $78 |
| Brimonidine | 27 | $1,885 | $70 |
| Latanoprost | 76 | $1,239 | $16 |
| Dorzolamide-Timolol | 18 | $633 | $35 |
| Timolol Maleate | 26 | $539 | $21 |
| Dorzolamide | 18 | $281 | $16 |
| Acyclovir | 17 | $227 | $13 |
2015: 4 drugs
| Brimonidine | 20 | $1,491 | $75 |
| Prednisolone Acetate | 18 | $1,472 | $82 |
| Dorzolamide-Timolol | 20 | $481 | $24 |
| Latanoprost | 32 | $453 | $14 |
2014: 4 drugs
| Prednisolone Acetate | 21 | $2,046 | $97 |
| Dorzolamide-Timolol | 18 | $681 | $38 |
| Erythromycin | 23 | $317 | $14 |
| Hydrocodone-Acetaminophen | 24 | $138 | $6 |
2013: 1 drug
| Prednisolone Acetate | 21 | $856 | $41 |
Money from drug and device companies
$18 in 2025
| 2025 | 1 | 1 | None | $18 |
| 2024 | 1 | 2 | None | $53 |
| 2023 | 1 | 1 | None | $149 |
| 2022 | 1 | 1 | $1,035 | $1,035 |
| 2019 | 1 | 1 | None | $125 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Tarsus Pharmaceuticals | Xdemvy | $18 | 1 payment
|
See the published payment
| Tarsus Pharmaceuticals | Meals · 2025-02-19 | Xdemvy | $18 |
See earlier years (2024, 2023, 2022, 2019)
2024: $53
| Tarsus Pharmaceuticals | Xdemvy | $53 | 2 payments
|
2023: $149
| Astellas Pharma US | None | $149 | 1 payment
|
2022: $1,035
| Bausch & Lomb Americas | Xipere | $1,035 | 1 payment
|
2019: $125
| Alimera Sciences | Iluvien | $125 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 80.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1013278118
- Licence
- CA A141803California A141803: Current · expires 2028-04-30
- Trained
- Mayo Medical School, 2012
- Group
- Stanford Health Care · County of Santa Clara
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207WX0107X (207WX0107X); Federal specialty code 207W00000X (207W00000X); Student in a training program (390200000X)
- Mailing address
- 2452 Watson Ct, Palo Alto, CA, 94303
- NPI first listed
- 2012-06-05
- NPI last updated
- 2024-04-04
- NPI record certified
- 2024-04-04
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2452 Watson Ct, Palo Alto, CA, 94303